Physician profile
Peter Choi
NPI 1588899256
$5,455.28
in general payments reported to CMS, 2019-2025
30 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $124 · 2021: $482 · 2022: $758 · 2023: $900 · 2024: $1,294 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,405.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $668.88 | 2019-2025 | Farxiga |
| Opko Pharmaceuticals, LLC | $538.71 | 2019-2025 | Rayaldee |
| Amgen INC. | $466.69 | 2021-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $415.40 | 2019-2024 | Jynarque |
| Aurinia Pharma U.S., INC. | $364.70 | 2021-2025 | Lupkynis |
| Travere Therapeutics, INC. | $361.44 | 2022-2025 | Filspari |
| Vifor Pharma, INC. | $355.02 | 2019-2024 | Veltassa |
| Fresenius USA Marketing, INC. | $353.46 | 2019-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $265.39 | 2022-2025 | Acthar |
| Glaxosmithkline, LLC. | $263.63 | 2021-2025 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $189.77 | 2021-2024 | |
| Genzyme Corporation | $142.79 | 2019-2024 | |
| Horizon Therapeutics Plc | $140.24 | 2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $126.93 | 2024-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $107.76 | 2021-2024 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $102.36 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $93.00 | 2022-2025 | Tarpeyo |
| Novo Nordisk INC | $86.62 | 2021-2025 | Ozempic, Rybelsus |
| Akebia Therapeutics INC | $64.54 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $48.63 | 2019 | |
| Tactile Systems Technology INC | $47.53 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.87 | 2023-2024 | Jardiance |
| Renalytix Ai, INC. | $41.01 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Shire North American Group INC | $33.23 | 2019 | |
| Alexion Pharmaceuticals, INC. | $30.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.45 | 2025 | |
| Recor Medical INC | $23.92 | 2024 | Paradise Renal Denervation System |
| Takeda Pharmaceuticals U.S.A., INC. | $21.99 | 2020 | |
| Boston Scientific Corporation | $16.00 | 2025 | Enhance Transcarotid Peripheral Access Kit |
| Arbor Pharmaceuticals, INC. | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.